Surrogate Endpoint¶
In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship.
Core Idea¶
Surrogate Endpoint is treated here as the recurring natural science, engineering, and health identity summarized by this source-grounded definition: In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship. In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a.
Scope of Application¶
-
Documented setting. A surrogate endpoint of a clinical trial is a laboratory measurement or a physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels.
-
Cardiovascular disease. In another case, AstraZeneca was accused of marketing rosuvastatin (Crestor) without providing hard endpoint data, relying instead on surrogate endpoints.
-
Cancer. More patient focused surrogate endpoints may offer a more meaningful alternative such as Overall Treatment Utility.
-
Infectious disease. In HIV/AIDS medicine, CD4 counts and viral loads are used as surrogate markers for drug approval for clinical trials.
-
Infectious disease. In hepatitis C medicine, the surrogate endpoint "Sustained Virological Response" has been used for the approval of expensive drugs known as Direct Acting Antivirals.
Clarity¶
A clear use of Surrogate Endpoint names the carrier, the operative relation, and the conditions under which the source treats the identity as present. The minimal definition is In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship.
Manages Complexity¶
Surrogate Endpoint compresses multiple natural science, engineering, and health details into a stable diagnostic relation. The source shows both the central mechanism—changes induced by a therapy on a surrogate endpoint are expected to reflect changes in a clinically meaningful endpoint.—and the practical consequence—the company countered that rosuvastatin had been tested on larger groups of patients than any other drug in the class, and that its effects should.
Abstract Reasoning¶
- Type the carrier. Identify the natural science, engineering, and health entities to which the claim applies.
- State the relation. Use the source-grounded identity: In clinical trials, a surrogate endpoint (also called a surrogate measure or surrogate marker) is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship.
- Check operation and conditions.
Knowledge Transfer¶
Within the home domain. Knowledge about Surrogate Endpoint transfers literally when a new case preserves the same carrier type, relation, and recognition test. A surrogate endpoint of a clinical trial is a laboratory measurement or a physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions or survives. In another case, AstraZeneca was accused of marketing rosuvastatin (Crestor) without providing hard endpoint data, relying instead on surrogate endpoints. Beyond the home domain. No canonical parent is asserted for Surrogate Endpoint.
Relationships to Other Abstractions¶
Current abstraction Surrogate Endpoint Domain-specific
Parents (1) — more general patterns this builds on
-
Surrogate Endpoint is a kind of Clinical Endpoint Domain-specific
Surrogate Endpoint is a kind of Clinical Endpoint with a stable domain-specific differentia.
Hierarchy path (1) — routes to 1 parentless root
- Surrogate Endpoint → Clinical Endpoint → Measurement
Neighborhood in Abstraction Space¶
Surrogate Endpoint sits in a moderately populated region (60th percentile for distinctiveness): it has near-neighbors but no dense thicket of look-alikes.
Family — Clinical Trial Design & Drug Safety (22 abstractions)
Nearest neighbors
- In silico clinical trials — 0.89
- Combination therapy — 0.86
- Surrogate Endpoint Problem — 0.85
- Self-licensing — 0.85
- Parabiosis — 0.84
Computed from structural-signature embeddings · 2026-10-08